Primary Immunodeficiencies (PID): driving diagnosis for optimal care in Europe
© Czerniawska and Modell; licensee BioMed Central Ltd. 2010
Published: 19 October 2010
Primary Immunodeficiencies (PID) are defects of the immune system that cause increased susceptibility to infections that are chronic, persistent, recurring, debilitating, and often fatal. There are more than 150 PID diseases, which affect more than 10 million people worldwide.
PID are often manageable, if properly evaluated and treated. However, awareness of these diseases is low amongst both primary care physicians and the general public. As a result, many patients are left undiagnosed. Delayed diagnosis and insufficient treatment leads to increased morbidity, mortality, and inflated medical costs, in addition to a life of chronic illness and suffering.
The Jeffrey Modell Foundation (JMF) was established in 1987 in memory of our son, Jeffrey, who died at the age of 15 after struggling with a PID. JMF’s mission is to assure early and precise diagnosis, meaningful treatments, and ultimately, cures of the ever increasing known PID diseases.
JMF initiated a Physician Education and Public Awareness Campaign to create greater awareness and encourage the earliest possible diagnose and precise treatment. This global campaign has had extraordinary results. Expert physicians from the Jeffrey Modell Centres Network of 72 Diagnostic and Research Centres and more than 196 Referral Centres worldwide have reported annual increases of more than 25% in the numbers of patients referred, patients followed, and patients identified with a specific PID. To date, more than 414 physicians from 176 teaching hospitals in 51 countries participate in the Jeffrey Modell Centres Network.
Nearly half of the Jeffrey Modell Diagnostic, Research and Referral Centres are located in Western, Central, and Eastern Europe. This European Network of Diagnostic Centres promotes improvements in the standard of care for patients with PID by fostering collaboration, measuring outcomes, sharing data, and serving the patients, families and caregivers of those affected by PID, and serves as a successful model for other diseases.
This article is published under license to BioMed Central Ltd.